Kenvue Inc(KVUE-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low19.13
Day High19.31
Open:19.19
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
RBC Capital Sticks to Its Hold Rating for Kenvue, Inc. (KVUE)
Motley Fool
Kimberly-Clark (KMB) Q2 2026 Earnings Call Transcript
Tipranks
Analysts Offer Insights on Consumer Goods Companies: Kenvue, Inc. (KVUE) and Turning Point Brands (TPB)
Tipranks
Analysts Offer Insights on Consumer Goods Companies: Vital Farms (VITL) and Kenvue, Inc. (KVUE)
Tipranks
Wall Street Analysts Are Neutral on Top Consumer Goods Picks
Motley Fool
3 Dividend Stocks That Are No-Brainer Buys for the Second Half of 2026
Motley Fool
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It
Tipranks
Barclays Reaffirms Their Hold Rating on Kenvue, Inc. (KVUE)
Motley Fool
An Overlooked Dividend King With a 54-Year Winning Streak Worth Buying Now
Motley Fool
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?
SYNDTGAM
U.S. appeals court revives more than 500 lawsuits against Tylenol-maker Kenvue over autism claims
A pharmacist faces shelves of Tylenol brand products at I.D.A. Concession Drug Mart in Hamilton, Ontario, on Monday, November 3, 2025. Kenvue, the maker of Tylenol, which has faced attacks from the White House and flagging demand for its products is set to be bought by Kimberly-Clark in a $48.7 billion deal.(Nick Iwanyshyn/The Globe and Mail)
Motley Fool
Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.
Motley Fool
Church & Dwight vs. Kimberly-Clark: Which Consumer Goods Stock Is a Better Buy in 2026?
Tipranks
RBC Capital Sticks to Its Hold Rating for Kenvue, Inc. (KVUE)
Motley Fool
SpaceX Stock Is Down 26% From Its Post-IPO High. History Says a $20,000 Investment Will Be Worth This Much by Mid-2027.
Motley Fool
This 4.5%-Yielding Dividend Stock Is Beating the S&P 500 and the Nasdaq. 3 Reasons That Can Continue in the Second Half of 2026
Motley Fool
2 Dividend Kings to Buy and Hold Forever
Motley Fool
Meet the Dividend King Stock That's Up 20% in 2026. Here's Why It Can Continue Outperforming the S&P 500 and Nasdaq-100 in the Second Half.
Motley Fool
3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio

Profile

Kenvue Inc. is a pure-play consumer health company. Its brand portfolio includes AVEENO(R), BAND-AID(R) Brand Adhesive Bandages, JOHNSON'S(R), LISTERINE(R), NEUTROGENA(R), TYLENOL(R) and ZYRTEC(R). Kenvue Inc. is based in SKILLMAN, N.J.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.